Common errors in the management of outpatients with inflammatory bowel disease;Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal

Gastroenterologia y Hepatologia

Volumn 30, Issue 8, 2007, Pages 469-486

  Gisbert, Javier P ^a,c   Gomollón, Fernando ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c Playa de Mojacar   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALAZOSULFAPYRIDINE; STEROID;

ENDOSCOPY; ENTERITIS; HUMAN; INTESTINE STENOSIS; MEDICAL DECISION MAKING; MEDICAL ERROR; OUTPATIENT; REVIEW; STEROID THERAPY; SURGICAL APPROACH; SURGICAL TECHNIQUE;

EID: 36049052000     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13110491     Document Type: Article

References (265)

1. Gisbert JP, Gomollon F. Common errors in the management of the seriously ill patient with inflammatory bowel disease. Gastroenterol Hepatol. 2007;30:294-314.
2. Reason J. Safety in the operating theatre (II): human error and organisational failure. Qual Saf Health Care. 2005;14:56-60.
3. Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am J Gastroenterol. 2005;100:1357-61.
4. Geboes K, Delabie J, Rutgeerts P, Vantrappen G. Endoscopy as a diagnostic tool in inflammatory bowel disease. Acta Chir Belg. 1989;89:106-10.
5. Oshitani N, Kitano A, Nakamura S, Obata A, Hashimura H, Hiki M, et al. Clinical and prognostic features of rectal sparing in ulcerative colitis. Digestión. 1989;42:39-43.
6. Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol. 1993;17:869-75.
7. Bernstein CN, Shanahan F, Anton PA, Weinstein WM. Patchiness of mucosal inflammation in treated ulcerative colitis: a prospective study. Gastrointest Endosc. 1995;42:232-7.
8. D'Haens G, Geboes K, Peeters M, Baert F, Ectors N, Rutgeerts P. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol. 1997;92:1275-9.
9. Okawa K, Aoki T, Sano K, Harihara S, Kitano A, Kuroki T. Ulcerative colitis with skip lesions at the mouth of the appendix: a clinical study. Am J Gastroenterol. 1998;93:2405-10.
10. Scott IS, Sheaff M, Coumbe A, Feakins RM, Rampton DS. Appendiceal inflammation in ulcerative colitis. Histopathology. 1998;33:168-73.
11. Kim B, Barnett JL, Kleer CG, Appelman HD. Endoscopic and histological patchiness in treated ulcerative colitis. Am J Gastroenterol. 1999;94:3258-62.
12. Yang SK, Jung HY, Kang GH, Kim YM, Myung SJ, Shim KN, et al. Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: an analysis in relation to medical therapy and disease extent. Gastrointest Endosc. 1999;49:743-7.
13. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000:CD000545.
14. Ohtaka M, Asakawa A, Kashiwagi A, Fujino MA, Kasai H, Matsumoto Y. Pericecal appendiceal abscess with drainage during colonoscopy. Gastrointest Endosc. 1999;49:107-9.
15. Yamagishi N, Iizuka B, Nakamura T, Suzuki S, Hayashi N. Clinical and colonoscopic investigation of skipped periappendiceal lesions in ulcerative colitis. Scand J Gastroenterol. 2002;37:177-82.
16. Matsumoto T, Nakamura S, Shimizu M, Iida M. Significance of appendiceal involvement in patients with ulcerative colitis. Gastrointest Endosc. 2002;55:180-5.
17. Dolz C, Vilella A, Andreu H, Riera J. Ulcerative colitis with segmental involvement. Gastroenterol Hepatol. 2003;26:64-9.
18. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin Gastroenterol Hepatol. 2005;3:11-24.
19. Byeon JS, Yang SK, Myung SJ, Pyo SI, Park HJ, Kim YM, et al. Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status. Inflamm Bowel Dis. 2005;11:366-71.
20. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5-36.
21. Zaitoun AM, Cobden I, Al Mardini H, Record CO. Morphometric studies in rectal biopsy specimens from patients with ulcerative colitis: effect of oral 5 amino salicylic acid and rectal prednisolone treatment. Gut. 1991;32:183-7.
22. Farmer RG, Hawk WA, Turnbull RB Jr. Clinical patterns in Crohn's disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627-35.
23. Berg DF, Bahadursingh AM, Kaminski DL, Longo WE. Acute surgical emergencies in inflammatory bowel disease. Am J Surg. 2002;184:45-51.
24. Gisbert JP, Gomollon F, Mate J, Figueroa JM, Alos R, Pajares JM. Treatment of stenosis due to Crohn's disease. Gastroenterol Hepatol. 2002;25:560-9.
25. Sachar DB. Ten common errors in the management of inflammatory bowel disease. Inflamm Bowel Dis. 2003;9:205-9.
26. Brower RA. Hydrostatic balloon dilation of a terminal ileal stricture secondary to Crohn's disease. Gastrointest Endosc. 1986;32:38-40.
27. Kirtley DW, Willis M, Thomas E. Balloon dilation of recurrent terminal ileal Crohn's stricture. Gastrointest Endosc. 1987;33:399-400.
28. Van Gossum A, Gay F, Cremer M. Enteroliths and Crohn's disease stricture treated by transendoscopic balloon dilation. Gastrointest Endosc. 1995;42:597.
29. Coffey MJ, Wright RA. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's studies: a prospective long-term analysis. Gastrointest Endosc. 1996;43:89-90.
30. Blomberg B. Endoscopic treatment modalities in inflammatory bowel disease. Endoscopy. 1992;24:578-81.
31. Williams AJ, Palmer KR. Endoscopic balloon dilatation as a therapeutic option in the management of intestinal strictures resulting from Crohn's disease. Br J Surg. 1991;78:453-4.
32. Blomberg B, Rolny P, Jarnerot G. Endoscopic treatment of anastomotic strictures in Crohn's disease. Endoscopy. 1991;23:195-8.
33. Neufeld DM, Shemesh EI, Kodner IJ, Shatz BA. Endoscopic management of anastomotic colon strictures with electrocautery and balloon dilation. Gastrointest Endosc. 1987;33:24-6.
34. Dobson HM, Robertson DA. Balloon catheter dilatation of an ileocolic stricture. Clin Radiol. 1988;39:202-4.
35. Couckuyt H, Gevers AM, Coremans G, Hiele M, Rutgeerts P. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut. 1995;36:577-80.
36. Gevers AM, Couckuyt H, Coremans G, Hiele M, Rutgeerts P. Efficacy and safety of hydrostatic balloon dilation of ileocolonic Crohn's strictures. A prospective long-term analysis. Acta Gastroenterol Belg. 1994;57:320-2.
37. Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L. Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc. 1995;42:252-5.
38. Breysem Y, Janssens JF, Coremans G, Vantrappen G, Hendrickx G, Rutgeerts P. Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results. Gastrointest Endosc. 1992;38:142-7.
39. Makowiec F, Starlinger M. Gastroduodenal involvement and circumscribed intestinal stricture in Crohn disease. Zentralbl Chir. 1998;123:338-43.
40. Tjandra JJ, Fazio VW, Lavery IC. Results of multiple strictureplasties in diffuse Crohn's disease of the small bowel. Aust N Z J Surg. 1993;63:95-9.
41. Sharif H, Alexander-Williams J. The role of strictureplasty in Crohn's disease. Int Surg. 1992;77:15-8.
42. Hurst RD, Cohen RD. The role of laparoscopy and strictureplasty in the management of inflammatory bowel disease. Semin Gastrointest Dis. 2000;11:10-7.
43. Cooke WT, Mallas E, Prior P, Allan RN. Crohn's disease: course, treatment and long term prognosis. Q J Med. 1980;49:363-84.
44. Travis SP, Stange EF, Lemann M, Oresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut. 2006;55 Suppl 1:16-35.
45. Yamamoto T, Bain IM, Allan RN, Keighley MR. An audit of strictureplasty for small-bowel Crohn's disease. Dis Colon Rectum. 1999;42:797-803.
46. Tjandra JJ, Fazio VW. Strictureplasty for ileocolic anastomotic strictures in Crohn's disease. Dis Colon Rectum. 1993;36:1099-103.
47. Fazio VW, Galandiuk S, Jagelman DG, Lavery IC. Strictureplasty in Crohn's disease. Ann Surg. 1989;210:621-5.
48. Dehn TC, Kettlewell MG, Mortensen NJ, Lee EC, Jewell DP. Ten-year experience of strictureplasty for obstructive Crohn's disease. Br J Surg. 1989;76:339-41.
49. Silverman RE, McLeod RS, Cohen Z. Strictureplasty in Crohn's disease. Can J Surg. 1989;32:19-22.
50. Fazio VW, Tjandra JJ, Lavery IC, Church JM, Milsom JW, Oakley JR. Long-term follow-up of strictureplasty in Crohn's disease. Dis Colon Rectum. 1993;36:355-61.
51. Yamamoto T, Keighley MR. Long-term results of strictureplasty for ileocolonic anastomotic recurrence in Crohn's disease. J Gastrointest Surg. 1999;3:555-60.
52. Resegotti A, Astegiano M, Sostegni R, Garino M, Fusi D, Longhin R. Stricture plasty in Crohn's disease. Indications and results. Minerva Chir. 2000;55:313-7.
53. Becker JM. Surgical therapy for ulcerative colitis and Crohn's disease. Gastroenterol Clin North Am. 1999;28:371-90.
54. Nugent FW, Roy MA. Duodenal Crohn's disease: an analysis of 89 cases. Am J Gastroenterol. 1989;84:249-54.
55. Ozuner G, Fazio VW. Management of gastrointestinal bleeding after strictureplasty for Crohn's disease. Dis Colon Rectum. 1995;38:297-300.
56. Ozuner G, Fazio VW, Lavery IC, Church JM, Hull TL. How safe is strictureplasty in the management of Crohn's disease? Am J Surg. 1996;171:57-60.
57. Spencer MP, Nelson H, Wolff BG, Dozois RR. Strictureplasty for obstructive Crohn's disease: the Mayo experience. Mayo Clin Proc. 1994;69:33-6.
58. Alexander-Williams J, Haynes IG. Up-to-date management of small-bowel Crohn's disease. Adv Surg. 1987;20:245-64.
59. Sayfan J, Wilson DA, Allan A, Andrews H, Alexander-Williams J. Recurrence after strictureplasty or resection for Crohn's disease. Br J Surg. 1989;76:335-8.
60. Pritchard TJ, Schoetz DJ Jr, Caushaj FP, Roberts PL, Murray JJ, Coller JA, et al. Strictureplasty of the small bowel in patients with Crohn's disease. An effective surgical option. Arch Surg. 1990;125:715-7.
61. Stebbing JF, Jewell DP, Kettlewell MG, Mortensen NJ. Recurrence and reoperation after strictureplasty for obstructive Crohn's disease: long-term results. Br J Surg. 1995;82:1471-4.
62. Serra J, Cohen Z, McLeod RS. Natural history of strictureplasty in Crohn's disease: 9-year experience. Can J Surg. 1995;38:481-5.
63. Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA. Reoperative rates for Crohn's disease following strictureplasty. Long-term analysis. Dis Colon Rectum. 1996;39:1199-203.
64. Hurst RD, Michelassi F. Strictureplasty for Crohn's disease: techniques and long-term results. World J Surg. 1998;22:359-63.
65. Tonelli F, Ficari F, Bagnoli S. Repair of stricture in Crohn's disease: treatment of choice? Chir Ital. 1995;47:15-23.
66. Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198-206.
67. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55 Suppl 1:36-58.
68. Kroser J, Srinivasan R. Drug therapy of inflammatory bowel disease in fertile women. Am J Gastroenterol. 2006;101 Suppl 3:633-9.
69. Katz JA. Endoscopy in the pregnant patient with inflammatory bowel disease. Gastrointest Endosc Clin N Am. 2002;12:635-46.
70. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:V1-16.
71. Cappell MS, Sidhom O. Multicenter, multiyear study of safety and efficacy of flexible sigmoidoscopy during pregnancy in 24 females with follow-up of fetal outcome. Dig Dis Sci. 1995;40:472-9.
72. Cappell MS, Colon VJ, Sidhom OA. A study at 10 medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci. 1996;41:2353-61.
73. Siddiqui U, Denise Proctor D. Flexible sigmoidoscopy and colonoscopy during pregnancy. Gastrointest Endosc Clin North Am. 2006;16:59-69.
74. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:278-82.
75. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131:283-311.
76. Ainley EJ, Winwood PJ, Begley JP. Measurement of serum electrolytes and phosphate after sodium phosphate colonoscopy bowel preparation: an evaluation. Dig Dis Sci. 2005;50:1319-23.
77. Rimensberger P, Schubiger G, Willi U. Connatal rickets following repeated administration of phosphate enemas in pregnancy: a case report. Eur J Pediatr. 1992;151:54-6.
78. Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad Med J. 2002;78:23-6.
79. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am. 2003;32:323-40.
80. Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch Gynecol Obstet. 2004;270:79-85.
81. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-92.
82. Mottet C, Juillerat P, Gonvers JJ, Froehlich F, Burnand B, Vader JP, et al. Pregnancy and Crohn's disease. Digestión. 2005;71:54-61.
83. Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology. 1993;105:1057-60.
84. Trallori G, D'Albasio G, Bardazzi G, Bonanomi AG, Amorosi A, Del Carlo P, et al. 5-Aminosalicylic acid in pregnancy: clinical report. Ital J Gastroenterol. 1994;26:75-8.
85. Marteau P, Tennenbaum R, Elefant E, Lemann M, Cosnes J. Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment Pharmacol Ther. 1998;12:1101-8.
86. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, et al. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology. 1998;114:23-8.
87. Norgard B, Fonager K, Pedersen L, Jacobsen BA, Sorensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut. 2003;52:243-7.
88. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, et al. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol. 2004;99:656-61.
89. Burtin P, Taddio A, Ariburnu O, Einarson TR, Koren G. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol. 1995;172:525-9.
90. Caro-Paton T, Carvajal A, Martin de Diego I, Martin-Arias LH, Álvarez Requejo A, Rodríguez Pinilla E. Is metronidazole teratogenic? A meta-analysis. Br J Clin Pharmacol. 1997;44:179-82.
91. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. Obstet Gynecol. 1993;82:348-52.
92. Sorensen HT, Larsen H, Jensen ES, Thulstrup AM, Schonheyder HC, Nielsen GL, et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother. 1999;44:854-6.
93. Diav-Citrin O, Shechtman S, Gotteiner T, Arnon J, Ornoy A. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology. 2001;63:186-92.
94. Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother. 1998;42:1336-9.
95. Larsen H, Nielsen GL, Schonheyder HC, Olesen C, Sorensen HT. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents. 2001;18:259-62.
96. Rodríguez-Pinilla E, Martínez-Frías ML. Corticosteroids during pregnancy and oral clefts: a case-control study. Teratology. 1998;58:2-5.
97. Carmichael SL, Shaw GM. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet. 1999;86:242-4.
98. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol. 2004;18:93-101.
99. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385-92.
100. Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65:240-61.
101. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99:443-6.
102. Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestión. 2000;62:249-54.
103. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124:9-17.
104. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT. Birht outcome in women treated with azathioprine or meccaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25:73-81.
105. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71:1051-5.
106. Bertschinger P, Himmelmann A, Risti B, Follath F. Cyclosporine treatment of severe ulcerative colitis during pregnancy. Am J Gastroenterol. 1995;90:330.
107. Anderson JB, Turner GM, Williamson RC. Fulminant ulcerative colitis in late pregnancy and the puerperium. J R Soc Med. 1987;80:492-4.
108. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-30.
109. Mahadevan U, Kane S, Sandborn WJ, Cohen RD, Hanson K, Terdiman JP, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-8.
110. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut. 2005;54:890.
111. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis. 2006;12:827-8.
112. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311-7.
113. Wilcox GM, Porensky RS. Acute colitis associated with etodolac. J Clin Gastroenterol. 1997;25:367-8.
114. Puspok A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon. Dis Colon Rectum. 2000;43:685-91.
115. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. Postgrad Med J. 1981;57:297-9.
116. Rampton DS, McNeil NI, Sarner M. Analgesic ingestion and other factors preceding relapse in ulcerative colitis. Gut. 1983;24:187-9.
117. Pearson DJ, Stones NA, Bentley SJ. Proctocolitis induced by salicylate and associated with asthma and recurrent nasal polyps. BMJ (Clin Res Ed). 1983;287:1675.
118. Walt RP, Hawkey CJ, Langman MJ. Colitis associated with non-steroidal anti-inflammatory drugs. BMJ (Clin Res Ed). 1984;288:238.
119. Rutherford D, Stockdill G, Hamer-Hodges DW, Ferguson A. Proctocolitis induced by salicylate. BMJ (Clin Res Ed). 1984;288:794.
120. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107:513-6.
121. Davies NM. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum. 1995;38:1311-21.
122. Evans JM, McMahon AD, Murray FE, McDevitt DG, Mac-Donald TM. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut. 1997;40:619-22.
123. Miner PB Jr. Factors influencing the relapse of patients with inflammatory bowel disease. Am J Gastroenterol. 1997;92: 1S-4S.
124. Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol. 2000;95:1949-54.
125. Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther. 2004;20:1035-43.
126. Takeuchi K, Smale S, Premchand P, Maiden L, Sherwood R, Thjodleifsson B, et al. Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:196-202.
127. Korzenik JR, Podolsky DK. Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:157-9.
128. Meyer AM, Ramzan NN, Heigh RI, Leighton JA. Relapse of inflammatory bowel disease associated with use of nonsteroidal anti-inflammatory drugs. Dig Dis Sci. 2006;51:168-72.
129. Guslandi M. Exacerbation of inflammatory bowel disease by nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors: fact or fiction? World J Gastroenterol. 2006;12:1509-10.
130. Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am J Gastroenterol. 2000;95:1946-8.
131. Domenech E. Antiinflamatorios no esteroideos y anticonceptivos orales en la enfermedad inflamatoria intestinal. Gastroenterología Práctica. 2002;11:24-26.
132. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol. 2002;97:910-4.
133. Reinisch W, Miehsler W, Dejaco C, Harrer M, Waldhoer T, Lichtenberger C, et al. An open-label trial of the selective cyclooxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia. Aliment Pharmacol Ther. 2003;17:1371-80.
134. Sandborn WJ, Stenson WF, Brynskov J, Lorenz RG, Steidle GM, Robbins JL, et al. Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin Gastroenterol Hepatol. 2006;4:203-11.
135. Biancone L, Tosti C, De Nigris F, Fantini M, Pallone F. Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. Gastroenterology. 2003;125:637-8.
136. Matuk R, Crawford J, Abreu MT, Targan SR, Vasiliauskas EA, Papadakis KA. The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:352-6.
137. Solem CA, Loftus EV Jr. Management of refractory inflammatory bowel disease. Gastroenterol Clin North Am. 2004;33:319-34, x.
138. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut. 2004;53:1190-7.
139. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116 Suppl 7A:44-9.
140. Semrin G, Fishman DS, Bousvaros A, Zholudev A, Saunders AC, Correia CE, et al. Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation. Inflamm Bowel Dis. 2006;12:1101-6.
141. Goodnough LT, Nissenson AR. Anemia and its clinical consequences in patients with chronic diseases. Am J Med. 2004;116 Suppl 7A:1-2.
142. Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6:142-150; discussion 151.
143. Wells CW, Lewis S, Barton JR, Corbett S. Effects of changes in hemoglobin level on quality of life and cognitive function in inflammatory bowel disease patients. Inflamm Bowel Dis. 2006;12:123-30.
144. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn disease. A randomized, controlled trial. Ann Intern Med. 1997;126:782-7.
145. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95:888-95.
146. García-López S, Gomollón F, Ortega-Zaya MA. Uso terapéutico del hierro intravenoso en la patología digestiva. Gastroenterología y hepatología continuada. Barcelona: Ediciones Doyma, S.A.; 2004. p. 25-9.
147. Rimon E, Kagansky N, Kagansky M, Mechnick L, Mashiah T, Namir M, et al. Are we giving too much iron? Low-dose iron therapy is effective in octogenarians. Am J Med. 2005;118:1142-7.
148. Zlotkin S, Arthur P, Antwi KY, Yeung G. Randomized, controlled trial of single versus 3-times-daily ferrous sulfate drops for treatment of anemia. Pediatrics. 2001;108:613-6.
149. Kawai M, Sumimoto S, Kasajima Y, Hamamoto T. A case of ulcerative colitis induced by oral ferrous sulfate. Acta Paediatr Jpn. 1992;34:476-8.
150. Reifen R, Matas Z, Zeidel L, Berkovitch Z, Bujanover Y. Iron supplementation may aggravate inflammatory status of colitis in a rat model. Dig Dis Sci. 2000;45:394-7.
151. Carrier J, Aghdassi E, Platt I, Cullen J, Allard JP. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. Aliment Pharmacol Ther. 2001;15:1989-99.
152. Aghdassi E, Carrier J, Cullen J, Tischler M, Allard JP. Effect of iron supplementation on oxidative stress and intestinal inflammation in rats with acute colitis. Dig Dis Sci. 2001;46:1088-94.
153. Carrier J, Aghdassi E, Cullen J, Allard JP. Iron supplementation increases disease activity and vitamin E ameliorates the effect in rats with dextran sulfate sodium-induced colitis. J Nutr. 2002;132:3146-50.
154. Erichsen K, Hausken T, Ulvik RJ, Svardal A, Berstad A, Berge RK. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease. Scand J Gastroenterol. 2003;38:543-8.
155. Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, et al. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand J Gastroenterol. 2005;40:1058-65.
156. Erichsen K, Ulvik RJ, Grimstad T, Berstad A, Berge RK, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:831-8.
157. De Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment Pharmacol Ther. 2005;22:1097-105.
158. a ed. Madrid: Asociación Española de Gastroenterología. SCM, S.L.; 2006. p. 465-75.
159. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol. 2004;76:74-8.
160. Juncà Piera J. Actualización de la ferroterapia parenteral. Med Clin (Barc). 2004;123:300-2.
161. Gasche C, Dejaco C, Reinisch W, Tillinger W, Waldhoer T, Fueger GF, et al. Sequential treatment of anemia in ulcerative colitis with intravenous iron and erythropoietin. Digestión. 1999;60:262-7.
162. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, et al. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 2001;96:2382-7.
163. Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34:286-90.
164. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anaemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol. 2004;39:454-8.
165. Schroder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, et al. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease: a randomized, controlled, open-label, multicenter study. Am J Gastroenterol. 2005;100:2503-9.
166. Kulnigg S, Gasche C. Systematic review: managing anaemia in Crohn's disease. Aliment Pharmacol Ther. 2006;24:1507-23.
167. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006;21:378-82.
168. Buning C, Lochs H. Conventional therapy for Crohn's disease. World J Gastroenterol. 2006;12:4794-806.
169. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006:CD000543.
170. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR. A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol. 1994;19:278-82.
171. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Gastroenterology. 1993;104:1293-301.
172. Rasmussen SN, Lauritsen K, Tage-Jensen U, Nielsen OH, Bytzer P, Jacobsen O, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol. 1987;22:877-83.
173. Mahida YR, Jewell DP. Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestión. 1990;45:88-92.
174. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379-88.
175. Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin Gastroenterol Hepatol. 2004;2:376-8.
176. Sandborn WJ. Evidence-based treatment algorithm for mild to moderate Crohn's disease. Am J Gastroenterol. 2003;98:S1-5.
177. De La Rue SA, Bickston SJ. Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr Opin Gastroenterol. 2006;22:365-9.
178. Orchard T, Probert CS, Keshav S. Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2006;24 Suppl 1:17-22.
179. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-71.
180. Marteau P, Probert CS, Lindgren S, Gassul M, Tan TG, Dignass A, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005;54:960-5.
181. D'Albasio G, Pacini F, Camarri E, Messori A, Trallori G, Bonanomi AG, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997;92:1143-7.
182. Piodi LP, Ulivieri FM, Cermesoni L, Cesana BM. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol. 2004;39:154-7.
183. Frieri G, Pimpo M, Galletti B, Palumbo G, Corrao G, Latella G, et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis. 2005;37:92-6.
184. Travis SP. Review article: induction therapy for patients with active ulcerative colitis. Aliment Pharmacol Ther. 2006;24 Suppl 1:10-6.
185. Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am. 2004;33:171-89, vii.
186. Papi C, Luchetti R, Gili L, Montanti S, Koch M, Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther. 2000;14:1419-28.
187. Nos P, Hinojosa J, Gomollon F, Ponce J. Budesonide in inflammatory bowel disease: a meta-analysis. Med Clin (Barc). 2001;116:47-53.
188. Kane SV, Schoenfeld P, Sandborn WJ, Tremaine W, Hofer T, Feagan BG. The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther. 2002;16:1509-17.
189. Yang YX, Lichtenstein GR. Corticosteroids in Crohn's disease. Am J Gastroenterol. 2002;97:803-23.
190. Scholmerich J. Review article: systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20 Suppl 4:66-74.
191. Rutgeerts P, Lofberg R, Malchow H, Lamers C, Olaison G, Jewell D, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331:842-5.
192. Gross V, Andus T, Caesar I, Bischoff SC, Lochs H, Tromm A, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol. 1996;8:905-9.
193. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41:209-14.
194. Bar-Meir S, Chowers Y, Lavy A, Abramovitch D, Sternberg A, Leichtmann G, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 1998;115:835-40.
195. D'Haens G, Verstraete A, Cheyns K, Aerden I, Bouillon R, Rutgeerts P. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease. Aliment Pharmacol Ther. 1998;12:419-24.
196. Otley A, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005:CD 000296.
197. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-9.
198. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-87.
199. Michetti P, Mottet C, Juillerat P, Felley C, Vader JP, Burnand B, et al. Severe and steroid-resistant Crohn's disease. Digestión. 2005;71:19-25.
200. Parkes M, Jewell DP. Review article: the management of severe Crohn's disease. Aliment Pharmacol Ther. 2001;15:563-73.
201. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
202. Van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG. Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol. 2001;51:601-7.
203. Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton IL, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004; 9:893-9.
204. Legido J, Gisbert JP, Pajares JM, Mate J. Bone metabolism changes in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2005;97:815-29.
205. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-64.
206. García-Planella E, Domènech E. Osteopenia and osteoporosis in inflammatory bowel disease. Gastroenterol Hepatol. 2004;27:417-24.
207. Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841.
208. Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:797-813.
209. Scott JA, Da Camara CC, Early JE. Raloxifene: a selective estrogen receptor modulator. Am Fam Physician. 1999;60:1131-9.
210. Compston J. Osteoporosis in inflammatory bowel disease. Gut. 2003;52:63-4.
211. Bernstein CN, Leslie WD. Therapy insight: osteoporosis in inflammatory bowel disease, advances and retreats. Nat Clin Pract Gastroenterol Hepatol. 2005;2:232-9.
212. Katz S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev Gastroenterol Dis. 2006;6:63-71.
213. Schoon EJ, Blok BM, Geerling BJ, Russel MG, Stockbrugger RW, Brummer RJ. Bone mineral density in patients with recently diagnosed inflammatory bowel disease. Gastroenterology. 2000;119:1203-8.
214. Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:715-29.
215. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-42.
216. Gisbert JP, Gomollón F, Mate J, Pajares JM. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2002;25:401-15.
217. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev. 2000:CD000067.
218. López-Sanroman A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24:45-9.
219. Ginsburg PM, Dassopoulos T. Steroid dependent ulcerative colitis: azathioprine use is finally «evidence-based». Inflamm Bowel Dis. 2006;12:921-2.
220. Kull E, Beau P. Compared azathioprine efficacy in ulcerative colitis and in Crohn's disease. Gastroenterol Clin Biol. 2002;26:367-71.
221. Peppercom MA. 6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come. Am J Gastroenterol. 1996;91:1689-90.
222. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
223. Caprilli R, Carratu R, Babbini M. A double-blind comparison of the effectiveness of azathioprine and sulfasalzine in idiopathic proctocolitis. Preliminary report. Dig Dis. 1975;20:115-120.
224. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-2.
225. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. BMJ. 1974;4:627-30.
226. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. BMJ (Clin Res Ed). 1982;284:1291-2.
227. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99:1122-8.
228. Mate-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2000;12:1227-33.
229. Orth T, Peters M, Schlaak JF, Krummenauer F, Wanitschke R, Mayet WJ, et al. Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol. 2000;95:1201-7.
230. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975;69:96-9.
231. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol. 2000;19:14-6.
232. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol. 2002;37:270-4.
233. Sood A, Midha V, Sood N, Avasthi G. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol. 2003;22:79-81.
234. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol. 1990;85:717-22.
235. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3.
236. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50:485-9.
237. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6- mercaptopurine. Am J Gastroenterol. 1996;91:1711-4.
238. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol. 2003;38:740-6.
239. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr. 1999;28:54-8.
240. Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004;99:462-5.
241. Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum. 1990;33:374-7.
242. López-Sanroman A, Bermejo F, Carrera E, García-Plaza A. Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther. 2004;20:161-6.
243. Paoluzi OA, Pica R, Marcheggiano A, Crispino P, Iacopini F, Iannoni C, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther. 2002;16:1751-9.
244. Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol. 1990;12:271-5.
245. Theodor E, Niv Y, Bat L. Imuran in the treatment of ulcerative colitis. Am J Gastroenterol 1981;76:262-6.
246. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr. 1990;117:809-14.
247. Actis GC, Rossetti S, Rizzetto M, Fadda M, Palmo A. Need for hospital admission in patients with ulcerative colitis during maintenance with azathioprine. Minerva Gastroenterol Dietol. 2004;50:97-101.
248. Stack WA, Williams D, Stevenson M, Logan RF. Immunosuppressive therapy for ulcerative colitis: results of a nationwide survey among consultant physician members of the British Society of Gastroenterology. Aliment Pharmacol Ther. 1999;13:569-75.
249. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol. 1989;7:1816-23.
250. Bergan S, Rugstad HE, Bentdal O, Sodal G, Hartmann A, Leivestad T, et al. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation. 1998;66:334-9.
251. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980;302:981-7.
252. Summers RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology. 1979;77:847-69.
253. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology. 1993;105:367-72.
254. Sandborn WJ, Tremaine WJ, Wolf DC, Targan SR, Sninsky CA, Sutherland LR, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology. 1999;117:527-35.
255. Mantzaris GJ, Archavlis E, Kourtessas D, Amberiadis P, Triantafyllou G. Oral azathioprine for steroid refractory severe ulcerative colitis. Am J Gastroenterol. 2001;96:2797-8.
256. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37: 674-8.
257. Chang JC, Cohen RD. Medical management of severe ulcerative colitis. Gastroenterol Clin North Am. 2004;33:235-50.
258. Vermeire S, Van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
259. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-2.
260. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
261. Hyams J, Markowitz J, Lerer T, Griffiths A, Mack D, Bousvaros A, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol. 2006;4:1118-23.
262. Markowitz J, Hyams J, Mack D, Leleiko N, Evans J, Kugathasan S, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-9.
263. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology. 2000;119:895-902.
264. Jaspers GJ, Verkade HJ, Escher JC, De Ridder L, Taminiau JA, Rings EH. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis. 2006;12:831-6.
265. Seidman EG. 6-mercaptopurine in maintaining remission in Crohn's disease: an old friend becomes a new hero. Gastroenterology. 2000;119:1158-60.